Published in Biotech Business Week, November 27th, 2006
Bio-Rad will purchase this business for approximately $20 million in cash. In addition, Bio-Rad will make a $3 million equity investment in Ciphergen. Ciphergen expects to close the transaction on or before November 1, 2006.
"With the approval of the sale of the instrument business, Ciphergen completes its transition into a specialty diagnostics company and is well-positioned to bring high-value molecular diagnostics to physicians and their patients," said Gail S. Page,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.